Search results for "stroke."

showing 10 items of 1178 documents

Posterior variant of alien limb syndrome with sudden clinical onset as self-hitting associated with thalamic stroke

2020

We present a case of sudden postischaemic onset of alien limb syndrome, with unintentional self-injury. Alien limb syndrome is an uncommon neurological disorder featured by uncontrolled and involuntary movements of a limb. Three variants of alien limb syndrome have been described: the anterior, featured by grasping of surrounding objects, the callosal, presenting with intermanual conflict, and the posterior, associated with involuntary levitation of the limb. Our patient suffered from an acute presentation of the posterior variant of the alien limb syndrome, resulting from an isolated thalamic stroke which was documented using 24-h computed tomography brain scan. Only one previous case of a…

medicine.medical_specialtyThalamic strokeAlien handNeurological disorderClinical onsetlcsh:RC346-42903 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationNeuroimagingmedicineSingle Case - General Neurology030212 general & internal medicineCerebrovascular diseaseStrokelcsh:Neurology. Diseases of the nervous systemInvoluntary movementbusiness.industryPosterior variant of alien limb syndromemedicine.diseaseSelf hittingbody regionsStrokeThalamic strokeSettore MED/26 - NeurologiaNeurology (clinical)Presentation (obstetrics)business030217 neurology & neurosurgery
researchProduct

RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study: Myocardial Dysfunction, Postoperative Neurocognitive Dysfunction, and 1 Year Foll…

2018

Background Remote ischemic preconditioning ( RIPC ) has been suggested to protect against certain forms of organ injury after cardiac surgery. Previously, we reported the main results of RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study, a multicenter trial randomizing 1403 cardiac surgery patients receiving either RIPC or sham‐ RIPC . Methods and Results In this follow‐up paper, we present 1‐year follow‐up of the composite primary end point and its individual components (all‐cause mortality, myocardial infarction, stroke and acute renal failure), in a sub‐group of patients, intraoperative myocardial dysfunction assessed by transesophageal echocardiography and the incidenc…

medicine.medical_specialtyTime FactorsMyocardial InfarctionNeurocognitive DisordersMyocardial Reperfusion InjuryNeuropsychological Tests030204 cardiovascular system & hematologyischemia/reperfusion injuryRisk Assessment03 medical and health sciencesCognition0302 clinical medicineDouble-Blind MethodRisk FactorsIschemiaGermanyMulticenter trialClinical StudiesClinical endpointHumansMedicineProspective Studies030212 general & internal medicineMyocardial infarctionCardiac Surgical ProceduresProspective cohort studyPropofolStrokeOriginal ResearchCardiovascular Surgerycardio‐vascular surgerybusiness.industryIncidenceProtective Factorsmedicine.diseaseSurgeryCardiac surgeryTreatment OutcomeIschemic Preconditioning MyocardialIschemic preconditioningremote ischemic preconditioningCardiology and Cardiovascular MedicinebusinessPropofolAnesthetics IntravenousEchocardiography Transesophagealmedicine.drug
researchProduct

Simultaneous cardiocerebral embolization in patients with atrial fibrillation

2020

medicine.medical_specialtyTime Factorsmedicine.medical_treatment[SDV]Life Sciences [q-bio]Myocardial Infarction030204 cardiovascular system & hematologyRisk AssessmentDecision Support Techniques03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineAtrial FibrillationIschaemic strokemedicineHumansThrombolytic TherapyIn patientMyocardial infarctionEmbolizationAngioplasty Balloon CoronaryIschemic StrokeThrombectomybusiness.industryAtrial fibrillationGeneral Medicinemedicine.diseaseCoronary embolismTreatment OutcomeIntracranial EmbolismConcomitantCardiologyStentsCardiology and Cardiovascular MedicinebusinessAlgorithms030217 neurology & neurosurgery
researchProduct

Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.

2021

Aims Despite aortic stenosis (AS) relief, patients undergoing transcatheter aortic valve implantation (TAVI) are at increased risk of developing heart failure (HF) within first months of intervention. Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have been shown to reduce the risk of HF hospitalization in individuals with diabetes mellitus (DM), reduced left ventricular ejection fraction (LVEF) and chronic kidney disease (CKD). However, the effect of SGLT-2 inhibitors on outcomes after TAVI is unknown. The Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) trial is designed to assess the clinical benefit and safety of the SGLT-2 inhibitor dapagliflozin in patients …

medicine.medical_specialtyTranscatheter aorticVentricular Function Leftlaw.inventionTranscatheter Aortic Valve Replacementchemistry.chemical_compoundRandomized controlled trialGlucosideslawInternal medicineDiabetes mellitusmedicineHumansProspective StudiesDapagliflozinBenzhydryl CompoundsHeart FailureEjection fractionbusiness.industryStroke VolumeAortic Valve Stenosismedicine.diseaseStenosisTreatment OutcomechemistryHeart failureAortic ValveCardiologyCardiology and Cardiovascular MedicinebusinessKidney diseaseEuropean journal of heart failureReferences
researchProduct

Right ventricular function and iron deficiency in acute heart failure

2021

Abstract Aims Iron deficiency (ID) is a frequent finding in patients with chronic and acute heart failure (AHF) along the full spectrum of left ventricular ejection fraction (LVEF). Iron deficiency has been related to ventricular systolic dysfunction, but its role in right ventricular function has not been evaluated. We sought to evaluate whether ID identifies patients with greater right ventricular dysfunction in the setting of AHF. Methods and results We prospectively included 903 patients admitted with AHF. Right systolic function was evaluated by tricuspid annular plane systolic excursion (TAPSE) and the ratio TAPSE/pulmonary artery systolic pressure (TAPSE/PASP). Iron deficiency was de…

medicine.medical_specialtyVentricular Dysfunction Right030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineVentricular Function Left03 medical and health sciences0302 clinical medicineLeft ventricle ejection fraction[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineSystoleAgedAged 80 and overHeart FailureIron deficiency.Ejection fractionAnemia Iron-DeficiencybiologyTransferrin saturationbusiness.industryIron deficiencyRight ventricle ejection fractionStroke VolumeGeneral MedicineMiddle AgedPrognosismedicine.disease[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemTricuspid annular plane systolic excursionFerritinBlood pressureHeart failureVentricular Function Rightbiology.proteinCardiologyFemaleCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusiness
researchProduct

Right Heart Dysfunction and Readmission Risk Across Left Ventricular Ejection Fraction Status in Patients With Acute Heart Failure.

2021

BACKGROUND: Right heart dysfunction (RHD) parameters are increasingly important in heart failure (HF). This study aimed to evaluate the association of advanced RHD with the risk of recurrent admissions across the spectrum of left ventricular ejection fraction (LVEF). METHODS AND RESULTS: We included 3383 consecutive patients discharged for acute HF. Of them, in 1435 patients (42.4%), the pulmonary artery systolic pressure could not be measured accurately, leaving a final sample size of 1948 patients. Advanced RHD was defined as the combination of a ratio of tricuspid annular plane systolic excursion/pulmonary artery systolic pressure of less than 0.36 and significant tricuspid regurgitation…

medicine.medical_specialtyVentricular Dysfunction RightHeart failureRegurgitation (circulation)Patient ReadmissionVentricular Function LeftreadmissionsVentricular Dysfunction LeftInterquartile rangemedicine.arteryInternal medicinemedicineHumansHeart FailureEjection fractionbusiness.industryStroke Volumeleft ventricular ejection fractionmedicine.diseasePrognosisBlood pressureSample size determinationHeart failurePulmonary arteryRight heartCardiologyVentricular Function RightCardiology and Cardiovascular Medicinebusinessright heart dysfunction
researchProduct

Evaluation of oral anticoagulation therapy: Rationale and design of the thrombEVAL study programme

2013

Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine. Increasing life expectancy, demographic changes, and novel oral anticoagulants have led to an increasing complexity of medical therapy. However, data on quality and management of VKA therapy with phenprocoumon in current medical care are limited. Our aim is to investigate the quality of OAC with VKA in current health care and to evaluate the potential for improvements.The investigator-initiated thrombEVAL study programme comprises two cohorts of patients treated with vitamin K antagonists for oral anticoagulation…

medicine.medical_specialtyVitamin KEpidemiologymedicine.drug_classAdministration OralVitamin kPhenprocoumonThromboembolismmedicineHumansProspective StudiesQuality of careIntensive care medicineOral anticoagulationQuality of Health Carebusiness.industryAnticoagulantsVitamin K antagonistClinical routineTelemedicineResearch DesignIschemic strokePhenprocoumonCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Journal of Preventive Cardiology
researchProduct

New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention

2016

ABSTRACTIntroduction: Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleeding events.Areas covered: In this paper, the authors retrospectively analyzed the relevant literature on the NOACs using the PubMed and Google Scholar databases.Expert commentary: Although warfarin is effective in cardioembolic stroke prevention, easier handling and more favorable risk-benefit profile often render NOACs a more preferable therapy choice for neurologists.…

medicine.medical_specialtyVitamin KPyridonesaspirinmedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyDabigatranAnticoagulation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEdoxabanmedicineHumansatrial fibrillationPharmacology (medical)030212 general & internal medicineIntensive care medicineRivaroxabanAspirinbusiness.industryGeneral Neurosciencenon vitamin-K oral anticoagulantWarfarinAnticoagulantsreverse therapyAtrial fibrillationThrombolysismedicine.diseasemeasure of monitoringStrokewarfarinchemistryAnesthesiaPyrazolesApixabanstroke preventionNeurology (clinical)businessmedicine.drugExpert Review of Neurotherapeutics
researchProduct

Antivitamin K Drugs in Stroke Prevention

2014

Among the different subtypes of ischaemic strokes, almost 20 % are of cardiac origin. Different are the causes of cardioembolic stroke, but the most common is the atrial fibrillation, a supraventricular arrhythmia. Appropriate use of antiplatelet drugs and anticoagulants after transient ischaemic attack (TIA) or ischaemic stroke depends on whether the underlying cause is cardioembolic or of presumed arterial origin. Adequate antiplatelet therapy is recommended for secondary prevention after cerebral ischaemia of presumed arterial origin, whether for patients with TIA and ischaemic stroke of cardiac origin, mainly due to atrial fibrillation. Vitamin K antagonists (VKAs) are highly effective …

medicine.medical_specialtyVitamin KSettore MED/09 - Medicina InternaAppropriate useInternal medicinemedicineAnimalsHumanscardiovascular diseasesRandomized Controlled Trials as TopicPharmacologySupraventricular arrhythmiabusiness.industryPatient choiceStandard treatmentAnticoagulantsVKAs Stroke preventionAtrial fibrillationmedicine.diseaseStrokeIschemic Attack TransientStroke preventionCardiologyCerebral ischaemiaCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsDiscovery and development of direct thrombin inhibitorsCurrent Vascular Pharmacology
researchProduct

Atrial fibrillation and chronic kidney disease: focus on rivaroxaban

2015

Renal insufficiency increases the risk of stroke and bleeding in atrial fibrillation patients. Although vitamin K antagonists reduce the risk of stroke in patients with moderate renal dysfunction, this observation is less clear in patients with renal impairment. Moreover, the risk of bleeding with vitamin K antagonists increases as renal function worsens. Maintaining international normalized ratio values within therapeutic targets is more difficult in patients with renal dysfunction, and those agents may cause warfarin-related nephropathy and vascular calcification. Rivaroxaban is the only nonvitamin K oral anticoagulant with a dose specifically tested in patients with moderate renal insuff…

medicine.medical_specialtyVitamin Kmedicine.drug_classRenal functionurologic and male genital diseasesNephropathyRivaroxabanInternal medicineAtrial FibrillationmedicineHumansRenal Insufficiency ChronicStrokeAgedRivaroxabanbusiness.industryHealth PolicyWarfarinAnticoagulantsAtrial fibrillationVitamin K antagonistmedicine.diseaseStrokeCardiologyWarfarinbusinessFactor Xa Inhibitorsmedicine.drugKidney diseaseJournal of Comparative Effectiveness Research
researchProduct